Instrument Inactif

Autres langues SCHERING-PLOUGH

Actions

SGP

US8066051017

Cours en clôture Nyse Autres places de cotation
- ^USD	-

2009	SCHERING-PLOUGH : troisième trimestre en ligne avec les attentes	AO
2009	Schering-Plough : BPA ajusté stable au 3e trimestre.	CF

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

SCHERING-PLOUGH : Announces Sponsorship of Rabies-Control Projects in India	02/11/09
SCHERING-PLOUGH : Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies	02/11/09
SCHERING-PLOUGH : U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma	30/10/09
SCHERING-PLOUGH : Standard & Poor's Announces Changes to U.S. Indices	29/10/09
SCHERING-PLOUGH : Reports Financial Results for 2009 Third Quarter	22/10/09
SCHERING-PLOUGH : Nobilon Advances Intranasal Seasonal Influenza Vaccine Into Proof of Concept Study	13/10/09
SCHERING-PLOUGH : Schedules Conference Call Webcast For 2009 Third Quarter Earnings	12/10/09
SCHERING-PLOUGH : SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector	06/10/09
SCHERING-PLOUGH : Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock	18/09/09
SCHERING-PLOUGH : Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients	14/09/09
SCHERING-PLOUGH : Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study	14/09/09
SCHERING-PLOUGH : New Non-Drowsy CLARITIN(R) 12-Hour Gets Allergy Sufferers Through Their Busy Day	01/09/09
SCHERING-PLOUGH : Announces Two European Filings	26/08/09
SCHERING-PLOUGH : ANNOUNCES FDA APPROVAL OF SAPHRIS(R) (asenapine): for acute treatment of schizophrenia in adults and manic or mixed episodes of bipolar I disorder with or without psychotic features in adults	14/08/09
SCHERING-PLOUGH : Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults	14/08/09
SCHERING-PLOUGH : Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)	12/08/09
SCHERING-PLOUGH : Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours	11/08/09
SCHERING-PLOUGH : PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration	10/08/09
SCHERING-PLOUGH : Shareholders Approve Merger With Merck	07/08/09
SCHERING-PLOUGH : to Webcast Special Meeting of Shareholders	06/08/09

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues SCHERING-PLOUGH

Actions

SGP

US8066051017

Autres langues

Filtres